Large Budget Grant Applications ( ≥ $500,000)
- Materials Required for ARAs
- Deadlines for Submitting ARAs
- Reminders for Competing Renewals (Type 2)
- FAQs about ARAs
For grant applications in which the subtotal direct costs in any one year equal or exceed $500,000, the National Cancer Institute (NCI) and the National Institutes of Health (NIH) require investigators to seek approval from the appropriate extramural program staff member prior to submitting applications to NIH’s Center for Scientific Review (CSR). The NIH Guide for Grants and Contracts’ Notices NOT-CA-02-029 and NOT-OD-02-004 state that approval must be sought six weeks prior to submitting such applications. However, approval for applications assigned to NCI’s Division of Cancer Control and Population Sciences (DCCPS), of which the Epidemiology and Genomics Research Program (EGRP) is a part, must be sought in the form of an Awaiting Receipt of Application (ARA) at least eight weeks prior to submission to CSR or NCI in order to complete the necessary internal processing.
Failure to seek approval prior to submission will result in the application not being accepted for review, and a delay in consideration until the next application receipt date. This policy applies to new (Type 1), competing renewal (formerly called “competing continuation” applications) (Type 2), competing revision (formerly called a competing supplement) (Type 3), and amended/resubmitted applications (A1). The policy does not apply to applications submitted in response to Requests for Applications (RFAs) or other funding opportunities with specified budget limits.
Unanticipated requests for unusually high amounts of direct costs are difficult for NIH Institutes and Centers to manage regardless of the merit of the grant application or the budget justification. ARAs help the NIH extramural Divisions, such as DCCPS, consider research projects with large awards as early as possible in the budget and program planning process. Investigators are encouraged to contact the appropriate EGRP Program Directors as early as possible in order to obtain assistance in submitting ARAs.
Materials Required for ARAs
To request approval for an ARA, submit the following materials to the EGRP Program Director at least 8 weeks prior to the anticipated receipt date:
- A letter requesting approval to submit a grant application to CSR in which the subtotal direct costs equal or exceed $500,000 in any year. The letter should also include the following details:
- Grant application title. If the ARA is for a resubmission, please include the grant number.
- Funding Opportunity Announcement (FOA). Please include the FOA number.
- Scientific Impact. Brief discussion of why the grant application is unique and/or scientifically original, and the potential impact on the related field of research.
- Budget. Subtotal direct costs, total direct costs, and total costs for each year.
Tip: Do not include subcontract facilities and administrative (F&A) expenses in the subtotal direct cost calculations for the ARA. View the NIH policy on applications that include consortium and contractual facilities and administrative costs.
- Budget Categories. In the spreadsheet provided [XLSX - 11KB], please indicate the costs for those budget categories that are driving the budget over $500,000.
- Draft budget pages with budget justification. Note:
- It is not necessary to have institutional sign-off at this point.
- For Competing Renewals (Type 2), NCI policy limits (to 10%) the increase in first-year direct costs that may be requested in any competing renewal R01, U01, or P01 application over the award amount in the last year of the prior project period (i.e., over the last non-competing continuation award).
- For Program Project (P01s), please provide a budget summary [XLSX - 26KB] for the Projects and Cores
- Abstract and specific aims, and study timeline, preferably in a Microsoft Word format.
- If the grant application is a resubmission, include brief responses to the more significant reviewer concerns; however, it is not necessary to provide responses to all reviewer concerns.
- Data sharing plan. Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html).
The Genomic Data Sharing (GDS) Policy applies to all NIH-funded research that generates large-scale human or non-human genomic data. Examples of projects that fall within the scope of the GDS Policy are available on the NCI Genomic Data Sharing webpage.
Data pertinent to the interpretation of genomic data, including the minimal phenotype information needed to reproduce the primary analysis - such as associated phenotype data (e.g., clinical information), exposure data, relevant metadata, and descriptive information (e.g., protocols or methodologies used) - will be shared. In addition, specimen acquisition, experimental procedures, and data processing and analysis methods (e.g., alignment algorithms, software versions, etc.) are required with data submission.
For proposed studies that fall within the scope of the NIH GDS Policy, please complete the GDS specific data sharing plan [PDF], and provide a data dictionary with information describing the phenotype variables that will be submitted with the genomic dataset (example [PDF]).
Deadlines for Submitting ARAs
The following table lists the grant application due dates for CSR by grant mechanism, followed by the dates by which EGRP must receive ARAs for that cycle. If the EGRP due date falls on a weekend or holiday, then the deadline is the next business day.
Be aware that approval given to submit a large-budget application is limited to the cycle (CSR receipt date) for which the proposal is being submitted.
|Grant Mechanism:||Cycle I||Cycle II||Cycle III|
|Research Grants - R01 AND U01 - new||5-Feb||5-Jun||5-Oct|
|ARA Deadline for EGRP||12-Dec||10-Apr||10-Aug|
|Research Grants - R01 AND U01 - renewal, resubmission, revision||5-Mar||5-Jul||5-Nov|
|ARA Deadline for EGRP||9-Jan||10-May||10-Sept|
|Program Project Grants and Center Grants - P Series new, renewal, resubmission, revision*||25-Jan||25-May||25-Sept|
|ARA Deadline for EGRP||30-Nov||30-Mar||31-July|
|New Investigator - R01 resubmissions (optional submission dates)||10-Apr||10-Aug||10-Dec|
|ARA Deadline for EGRP||13-Feb||15-Jun||15-Oct|
|All Mechanisms Cited Above (new, renewal, resubmission, revision) for AIDS and AIDS-Related Applications||7-May||7-Sept||7-Jan|
|ARA Deadline for EGRP||12-Mar||13-July||12-Nov|
NIH Study Section Members, Boards/Councils
NIH has an alternate schedule for submission and review of large-budget R01, R21, and R34 (including AIDS-related) grant applications received from members of chartered NIH Study Sections and selected other advisory groups in recognition of their outstanding service to NIH. Eligible are appointed members of chartered standing NIH Study Sections, Boards of Scientific Counselors, Advisory Boards or Councils, the Peer Review Advisory Committee (PRAC), and peer reviewers who have served as regular or temporary members six times in 18 months. The schedule, described below, permits periods of continuous submission so that applications may be submitted as soon as they are completed. Applications are reviewed no later than 120 days after receipt. To enable timely second-level review, the following National Cancer Advisory Board (NCAB) dates will apply. If time permits, applications may be moved to earlier NCAB dates following review.
Investigators who intend to submit a large RO1 application under the continuous submission policy will be required to submit their ARA eight weeks prior to the anticipated submission date.
|NCAB Round||Submission Period for Continuous Submission|
|May||August 17 – December 16|
|October||December 17 – April 16|
|January||April 17 – August 16|
See the NIH Guide Notice, NOT-OD-17-042.
New Investigators who submit an amended application under the policy to shorten the review cycle for New Investigator R01s may not have sufficient time between when the summary statement is released and the next application receipt date to meet the required eight week submission deadline for an ARA. Nevertheless, an ARA is still required if the subtotal direct costs are equal to or exceed $500,000 in any year.
Be aware that:
- Participating Study Sections will schedule meetings so that New Investigators receive their summary statements no later than March 10, July 10, or November 10.
- Resubmission applications for consideration at the next cycle must be submitted by April 10, August 10, or December 10
- In cases where this is a short time period between receipt of the summary statement and the CSR application receipt due date, the investigator should contact Program staff to discuss a suitable deadline for submission of the ARA. See the NIH Guide Notice, NOT-OD-12-001.
Reminders for Competing Renewals (Type 2)
In 2008, NCI changed its funding policy for all competing renewal (Type 2) applications to cap first-year direct costs so that they generally do not exceed an increase of 10% over the direct costs awarded for the last year of the prior project period (i.e., the last Type 5 award). See the NIH Guide Notice, NOT-CA-08-026, and contact your Program Director for more information.
FAQs about ARAs
- Q: If I am submitting an amended application and my original application had an ARA that was approved, do I need to submit another ARA?
A. Yes. You must always submit an ARA when your application’s subtotal direct costs equal or exceed $500,000.
- Q: Should I wait to hear if my ARA has been approved before moving forward with submitting my application?
A: Approval of your ARA is required prior to submission. However, you should continue to prepare the application for submission during the ARA review process.
- Q: Once the ARA is approved, does NCI allow changes to the budget?
A: The investigator is expected to comply with the budget that was approved in the ARA request. However, decreases in direct costs are permitted without further NCI approval. If an increase in direct costs is anticipated, the investigator’s Program Director should be contacted to determine whether further approval is required.